EveliQure Biotechnologies GmbH
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.eveliqure.com
ShigETEC Vaccine Study in Bangladesh
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Other: Placebo
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Eveliqure Biotechnologies GmbH
- Target Recruit Count
- 180
- Registration Number
- NCT05987488
- Locations
- 🇧🇩
International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b), Dhaka, Bangladesh
Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
Phase 1
Completed
- Conditions
- Gastrointestinal DiseaseReactive ArthritisDiarrheal Disease, Infectious
- Interventions
- Biological: ShigETEC live, attenuated, oral vaccineDrug: Placebo
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Eveliqure Biotechnologies GmbH
- Target Recruit Count
- 84
- Registration Number
- NCT05409196
- Locations
- ðŸ‡ðŸ‡º
Debreceni Egyetem, Klinikai Központ, Belgyógyászati Klinika, Klinikai Farmakológiai Részleg, Debrecen, Hungary
© Copyright 2025. All Rights Reserved by MedPath